Lumos Pharma, Inc.

and welcome to lumos pharma first quarter 2024 financial results and clinical programs update call at this time all participants are in a listen only mode a brief question and answer session will follow the formal presentation if anyone should require operator assistance during the conference please press star 0 on your telephone keypad as a reminder this conference is being recorded It is now my pleasure to introduce your host, Ms. Lisa Miller, Vice President, Investor Relations. Thank you, Ms. Miller. You may begin.

Ms.

Miller, go ahead. Thank you, Operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports filed with SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements. Information presented on this call is contained in the press release we issued yesterday afternoon and in our Form 8-K, which may be accessed from the Investors page of the Loomis Pharma website. Speaking on today's call will be Rick Hawkins, CEO and Chairman, John McHugh, President and Chief Scientific Officer, and Lori Lawley, Chief Financial Officer. Dr. Paduk Chauhanan, Chief Medical Officer, will also join the call for the question and answer session. It's now my pleasure to turn the call over to Rick for our opening remarks.